Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers

por Medjebar, Soleine, Truntzer, Caroline, Perrichet, Anaïs, Limagne, Emeric, Fumet, Jean-David, Richard, Corentin, Elkrief, Arielle, Routy, Bertrand, Rébé, Cédric, Ghiringhelli, François
Publicado 2020